SG Americas Securities LLC Sells 152,758 Shares of Dyne Therapeutics, Inc. $DYN

SG Americas Securities LLC lowered its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 57.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 112,626 shares of the company’s stock after selling 152,758 shares during the quarter. SG Americas Securities LLC’s holdings in Dyne Therapeutics were worth $2,042,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. T. Rowe Price Investment Management Inc. increased its position in shares of Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the last quarter. Orbis Allan Gray Ltd acquired a new position in shares of Dyne Therapeutics during the 4th quarter worth approximately $93,926,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Dyne Therapeutics in the second quarter valued at $30,378,000. Perceptive Advisors LLC raised its holdings in Dyne Therapeutics by 543.7% in the 4th quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock valued at $68,048,000 after acquiring an additional 2,938,500 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Dyne Therapeutics by 572.9% during the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock worth $38,119,000 after purchasing an additional 2,565,570 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DYN. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a report on Friday, May 15th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Sanford C. Bernstein raised their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Finally, TD Cowen started coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $34.17.

Insider Activity

In other Dyne Therapeutics news, Director Brian S. Posner acquired 2,000 shares of the stock in a transaction dated Monday, June 8th. The stock was purchased at an average cost of $16.94 per share, with a total value of $33,880.00. Following the transaction, the director owned 24,500 shares in the company, valued at approximately $415,030. The trade was a 8.89% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Erick Lucera sold 2,362 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the sale, the chief financial officer owned 121,563 shares in the company, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have bought 9,000 shares of company stock valued at $156,800 and have sold 2,334,279 shares valued at $46,221,906. Insiders own 9.46% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $21.79 on Thursday. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The company has a market cap of $3.60 billion, a price-to-earnings ratio of -6.77 and a beta of 1.06. The firm has a 50 day simple moving average of $18.55 and a 200 day simple moving average of $18.13.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the business posted ($1.05) earnings per share. Research analysts predict that Dyne Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.